Xinming Su
- Immunology top 5%
- Immunotherapy and Immune Responses 6
- Immune cells in cancer 4
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 6
- Bone health and treatments 5
-
- MicroRNA in disease regulation 2
-
- Histone Deacetylase Inhibitors Research 3
- Epigenetics and DNA Methylation 3
-
- Multiple Myeloma Research and Treatments 4
- Co-authors
- Daniel F. HoftGuangyong PengEddy C. HsuehYanping ZhangJian YeKatherine N. WeilbaecherRoberta FaccioMelissa A. Meyer
- Cited by
- ImmunologyOncologyCancer Research
- Partner nations
- United StatesChinaCanada
In The Last Decade
Xinming Su
33 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 76
- Immunology 615
- Oncology 613
- Cancer Research 153
- Microbiology 5
- Molecular Biology 424
Countries citing papers authored by Xinming Su
This map shows the geographic impact of Xinming Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinming Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinming Su more than expected).
Fields of papers citing papers by Xinming Su
This network shows the impact of papers produced by Xinming Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinming Su. The network helps show where Xinming Su may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xinming Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 0 | |
| 5 | 2023 | 10 | |
| 6 | 2020 | 5 | |
| 7 | 2020 | 43 | |
| 8 | 2020 | 31 | |
| 9 | 2018 | 49 | |
| 10 | 2016 | 12 | |
| 11 | 2016 | 124 | |
| 12 | 2015 | 49 | |
| 13 | 2015 | 25 | |
| 14 | 2015 | 13 | |
| 15 | 2012 | 34 | |
| 16 | 2011 | 66 | |
| 17 | 2011 | 13 | |
| 18 | 2011 | 69 | |
| 19 | 2010 | 10 | |
| 20 | 2009 | 265 |
About Xinming Su
Xinming Su is a scholar working on Microbiology, Oncology, Immunology, Hematology and Cancer Research, having authored 38 papers that have together received 1.2k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (6 papers), Cancer Immunotherapy and Biomarkers (6 papers), Bone health and treatments (5 papers), Multiple Myeloma Research and Treatments (4 papers), Immune cells in cancer (4 papers), Histone Deacetylase Inhibitors Research (3 papers), Epigenetics and DNA Methylation (3 papers) and MicroRNA in disease regulation (2 papers). The work is most often cited by research in Immunology (615 citations), Oncology (613 citations), Cancer Research (153 citations), Microbiology (5 citations) and Molecular Biology (424 citations). Xinming Su has collaborated with scholars based in United States, China and Canada. Frequent co-authors include Daniel F. Hoft, Guangyong Peng, Eddy C. Hsueh, Yanping Zhang, Jian Ye, Katherine N. Weilbaecher, Roberta Faccio, Melissa A. Meyer, David G. DeNardo and Sheila A. Stewart. Their work appears in journals such as Cancer Research, The Journal of Immunology, Oncotarget, JCI Insight and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.